Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $123,436.80 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $21.43, for a total transaction of $123,436.80. Following the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at approximately $527,006.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Christine Ring also recently made the following trade(s):

• On Monday, July 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.81, for a total value of $119,865.60.
• On Wednesday, June 12th, Christine Ring sold 1,900 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.01, for a total value of $32,319.00.
• On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.00, for a total value of $6,800.00.
• On Monday, June 3rd, Christine Ring sold 1,596 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.01, for a total transaction of $27,147.96.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $20.78 on Friday. The business’s 50 day simple moving average is $19.32 and its 200-day simple moving average is $14.88. Nurix Therapeutics, Inc. has a 1 year low of $4.22 and a 1 year high of $24.38. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -7.12 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The business had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $19.35 million. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NRIX. ProShare Advisors LLC raised its position in Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares during the period. Public Employees Retirement System of Ohio raised its holdings in Nurix Therapeutics by 3.7% during the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after buying an additional 1,820 shares during the period. Raymond James & Associates lifted its position in Nurix Therapeutics by 3.1% in the fourth quarter. Raymond James & Associates now owns 101,006 shares of the company’s stock worth $1,042,000 after buying an additional 3,018 shares during the last quarter. GAMMA Investing LLC boosted its stake in Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after buying an additional 3,424 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in Nurix Therapeutics by 67.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after acquiring an additional 3,793 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have weighed in on NRIX shares. Royal Bank of Canada upped their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Friday, July 12th. JPMorgan Chase & Co. increased their price target on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Robert W. Baird raised their price target on Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. Truist Financial assumed coverage on Nurix Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Piper Sandler reissued an “overweight” rating and set a $35.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.67.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.